We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Titan Pharmaceuticals Inc (TTNP) USD0.001

Sell:$1.29 Buy:$1.41 Change: $0.06 (4.55%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
Change: $0.06 (4.55%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
Change: $0.06 (4.55%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. It operates in one business segment, which provides the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. Its product Probuphine implant is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, namely Kappa Opioid Agonist Peptide Program and Nalmefene Development Program. Its kappa opioid agonist peptide (TP-2021) uses ProNeura technology to provide a non-addictive treatment for certain types of pain.

Contact details

400 Oyster Point Blvd Ste 505
United States
+1 (650) 2444990

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$14.28 million
Shares in issue:
9.91 million
United States
US dollar

Key personnel

  • Marc Rubin
    Executive Chairman of the Board
  • Katherine DeVarney
    President, Chief Operating Officer, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.